Skip to content
Sign in

ADMA · NASDAQ

ADMA Biologics (ADMA) Stock Price & Fundamentals

$344.31−0.51%−$1.76End-of-day price as of Oct 9, 2026

ADMA Biologics (ADMA) closed at $344.31 on Oct 9, 2026, down 0.51% from the previous close of $346.07.

Share price, past year

1Y +1.88%

52-week range $323.50 – $379.10. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$344.31
Sep 30, 2026$351.12
Aug 31, 2026$341.19
Jul 31, 2026$363.96
Jun 30, 2026$365.34
May 29, 2026$362.16
Apr 30, 2026$354.87
Mar 31, 2026$347.06
Feb 27, 2026$337.26
Jan 30, 2026$329.34
Dec 31, 2025$341.75
Nov 28, 2025$352.31
Oct 31, 2025$342.71

Key statistics

Market cap
$77.59B
P/E (TTM)
491.9
EPS (TTM)
$0.70
Revenue (TTM)
$512.28M
Net income (TTM)
$168.96M
Shares outstanding
225.4M
Dividend yield
—
52-week range
$323.50 – $379.10

ADMA Biologics's market cap is $77.59B, based on a share price of $344.31 and 225.4M shares outstanding as of Jun 30, 2026.

Financials

ADMA Biologics reported revenue of $510.17M for fiscal 2025, up 19.63% from fiscal 2024.

ADMA Biologics earned net income of $146.93M in fiscal 2025, a net margin of 28.8%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
ADMA Biologics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$510.17M+19.6%$146.93M28.8%$0.60$27.82M
FY2024ended Dec 31, 2024$426.45M+65.2%$197.67M46.4%$0.81$110.45M
FY2023ended Dec 31, 2023$258.22M+67.6%−$28.24M−10.9%−$0.13$4.03M
FY2022ended Dec 31, 2022$154.08M+90.4%−$65.90M−42.8%−$0.33−$73.42M
FY2021ended Dec 31, 2021$80.94M+91.7%−$71.65M−88.5%−$0.51−$125.88M
FY2020ended Dec 31, 2020$42.22M+43.9%−$75.75M−179.4%−$0.88−$114.73M
FY2019ended Dec 31, 2019$29.35M+72.8%−$48.28M−164.5%−$0.89−$80.01M
FY2018ended Dec 31, 2018$16.99M−25.4%−$65.74M−387.1%−$1.45−$64.77M
FY2017ended Dec 31, 2017$22.76M+113.5%−$43.76M−192.3%−$1.91−$39.95M
FY2016ended Dec 31, 2016$10.66M—−$19.52M−183.1%−$1.61−$18.34M
ADMA Biologics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$124.40M$37.82M$0.16
Q1 FY2026ended Mar 31, 2026$114.49M$45.33M$0.19
Q4 FY2025ended Dec 31, 2025$139.16M$49.38M$0.20
Q3 FY2025ended Sep 30, 2025$134.22M$36.43M$0.15
Q2 FY2025ended Jun 30, 2025$121.98M$34.22M$0.14
Q1 FY2025ended Mar 31, 2025$114.80M$26.90M$0.11
Q4 FY2024ended Dec 31, 2024$117.55M$111.90M$0.45
Q3 FY2024ended Sep 30, 2024$119.84M$35.91M$0.15

Company profile

Name
ADMA Biologics Inc
Ticker
ADMA
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
C/O Adma Biologics, Inc., 465 State Route 17, Ramsey, NJ 07446
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001368514

Recent SEC filings

Frequently asked questions

What is ADMA Biologics's stock price?

ADMA Biologics (ADMA) closed at $344.31 on Oct 9, 2026, down 0.51% from the previous close of $346.07.

What is ADMA Biologics's market cap?

ADMA Biologics's market cap is $77.59B, based on a share price of $344.31 and 225.4M shares outstanding as of Jun 30, 2026.

How much revenue does ADMA Biologics make?

ADMA Biologics reported revenue of $510.17M for fiscal 2025, up 19.63% from fiscal 2024.

What is ADMA's P/E ratio?

ADMA Biologics's price-to-earnings ratio is 491.9, based on trailing twelve-month diluted EPS of $0.70.

Does ADMA Biologics pay a dividend?

ADMA Biologics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from ADMA Biologics Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures